Related Experiment Video
Updated: Jul 8, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Thrombomodulin gene polymorphisms in brain infarction and mortality after stroke
Jean-Marc Olivot1, Julien Labreuche, Thomas De Broucker
1INSERM U698 and Denis Diderot University - Paris VII, Dept. of Neurology and Stroke Center, Bichat University Hospital, Paris, France.
Journal of Neurology
|January 22, 2008
Summary
Genetic variations in thrombomodulin do not influence soluble thrombomodulin levels or the risk of brain infarction and subsequent mortality. These thrombomodulin gene polymorphisms are not linked to stroke outcomes.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Neurology
Background:
- Thrombomodulin (TM) is crucial for regulating thrombin generation and cellular activation on endothelial surfaces.
- TM gene polymorphisms have been previously linked to cardiovascular events like coronary events and brain infarction.
- Soluble thrombomodulin (sTM) concentration was found to influence brain infarction risk and prognosis in prior research.
Purpose of the Study:
- To investigate the association between three specific thrombomodulin gene polymorphisms (-1748G/C, -1208/-1209delTT, +1418C/T) and sTM levels.
- To determine if these polymorphisms affect the risk of brain infarction.
- To evaluate the impact of these polymorphisms on 5-year mortality after stroke.
Main Methods:
- Analysis of 474 brain infarction cases and 483 controls from the GENIC study.
- Genotyping for three thrombomodulin gene polymorphisms and measurement of sTM levels.
- Statistical analysis including single locus, haplotype, and survival analyses for brain infarction risk and mortality.
Main Results:
- The three studied thrombomodulin gene polymorphisms were in linkage disequilibrium and formed three major haplotypes.
- No significant influence of these polymorphisms or haplotypes on sTM concentration was observed (P > 0.16).
- No significant association was found between the polymorphisms and brain infarction risk or 5-year vascular/total mortality (P > 0.64).
Conclusions:
- The investigated thrombomodulin gene polymorphisms do not appear to affect sTM levels.
- These specific thrombomodulin gene polymorphisms are not associated with an increased risk of brain infarction.
- The studied polymorphisms do not correlate with mortality risk following a stroke.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...